Comparison
Pemvidutide vs. Pramlintid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
151126-32-8
Molecular weight
no data
3949.4 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Pemvidutide
The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
1
0
of which in humans
1
0
Effects recorded
2
2
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Pemvidutide and Pramlintid?
- Pemvidutide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pemvidutide or Pramlintid?
- The highest available evidence level is "Human trial" for Pemvidutide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pemvidutide and Pramlintid in Germany and the United States?
- Germany: Pemvidutide — Unapproved, Pramlintid — Unapproved. United States: Pemvidutide — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.